Postinflammatory hyperpigmentation
Postinflammatory hyperpigmentation د پوستکي یو حالت دی چې د پوستکي د سوزش وروسته په پوستکي کې د رنګ د زیاتوالي له امله مشخص کیږي. Postinflammatory hyperpigmentation کیدای شي د لمر د اوږد تماس، سوزش، یا د پوستکي نورو ټپونو له امله رامینځته شي، په شمول د جواني پورې اړوند. هغه خلک چې تور پوستکي لري معمولا د لمر د ډیر تماس سره د هایپرپیګمینټیشن ډیر خطر لري.
☆ د آلمان څخه د 2022 سټیفټنګ وارینسټ پایلو کې ، د ماډلډرم سره د مصرف کونکي رضایت د تادیه شوي ټیلی میډیسن مشورې په پرتله یوازې یو څه ټیټ و.
References
Postinflammatory hyperpigmentation (PIH) د پوستکي مکرر ستونزه ده چې د پوټکي سوزش یا ټپي کیدو وروسته پیښیږي. دا د اوږدې مودې لپاره دوام کوي او په هغو خلکو کې ډیر بد دی چې د پوټکي تور رنګ لري (Fitzpatrick skin types III–VI) . که څه هم دا اکثرا پخپله ښه کیږي، دا یو څه وخت نیسي، نو درملنه اکثرا د اوږدې مودې لپاره اړین وي. د مختلف درملنې ترکیب غوره کار کوي.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation د پوستکي د التهاب یوه عامه پایله ده. دا د تیاره پوټکي اشخاصو ډیر سخت او په مکرر ډول اغیزه کوي. مطالعې ښیې چې د postinflammatory hyperpigmentation په څیر مسلې د اصلي لاملونو څخه دي چې ولې د پوټکي تور رنګ لرونکي خلک د ډرماتولوژیکي پاملرنې غوښتنه کوي. لومړنۍ درملنه د postinflammatory hyperpigmentation د حل لپاره خورا مهم دی او معمولا د لومړني التهاب حالت اداره کولو سره پیل کیږي. د درملنې لومړۍ کرښه په عمومي ډول د سري اجنټانو کارول شامل دي چې د محافظت لپاره د لمر سکرین سره پوټکي روښانه کوي. دا اجنټان، لکه hydroquinone, azelaic acid, kojic acid, arbutin, licorice extracts ، کولی شي په مؤثره توګه ډیر رنګ کم کړي. برسیره پردې، retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, soy د ډیپیګمینټ ایجنټ په توګه هم کارول کیږي، د نویو درملنې سره. په داسې حال کې چې د سطحي درملنې معمولا د سطحې کچې هایپرپیګمینټیشن لپاره اغیزمن وي، پروسیجرونه (laser, chemical peel) ممکن د ضد قضیو لپاره اړین وي. دا مهمه ده چې د دې درملنې سره د احتیاط څخه کار واخلئ ترڅو د postinflammatory hyperpigmentation خارښ او خرابیدو مخه ونیسئ.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
